PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
149.60%
Cash & equivalents growing 149.60% while TRVN's declined -10.65%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
149.60%
Below half of TRVN's -10.65%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
133.42%
Below half of TRVN's -11.18%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
835.01%
≥ 1.5x TRVN's 52.12%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1079.37%
≥ 1.5x TRVN's 29.50%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
135.47%
Below half of TRVN's -11.00%. Michael Burry sees a potential red flag for stagnation or capital shortage.
69.91%
Above 1.5x TRVN's 12.57%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-41.82%
Higher Short-Term Debt Growth compared to TRVN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-49.13%
Less than half of TRVN's 0.25%. David Dodd sees fewer expansions in other current obligations.
-44.50%
Less than half of TRVN's 6.08%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-44.50%
Less than half of TRVN's 5.53%. David Dodd sees far fewer liability expansions relative to competitor.
7.98%
Above 1.5x TRVN's 0.48%. Michael Burry suspects heavy new equity expansion or dilution.
4.22%
Below half TRVN's -12.54%. Michael Burry suspects major net losses or high dividends vs. competitor.
-271.57%
Less than half of TRVN's 11.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
132.15%
Below half TRVN's -11.98%. Michael Burry sees potential underperformance in building shareholder capital.
135.47%
Below half TRVN's -11.00%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-41.82%
Higher Total Debt Growth compared to TRVN's zero value, indicating worse performance.
-152.72%
Less than half of TRVN's 10.65%. David Dodd sees better deleveraging or stronger cash buildup than competitor.